November 5, 2024
StemRIM Inc.

StemRIM Announces Patent Registration in Japan for the HMGB1 Peptide, Redasemtide

Osaka, Japan, November 5, 2024 – StemRIM Inc. (TSE:4599, President and CEO: Masatsune Okajima; "StemRIM" or "Company") announces that a medical use patent for the use of the peptides of "Regeneration-Inducing Medicine™" development candidate, Redasemtide, will soon be registered in Japan as detailed below.

Title of Invention	:	Therapeutic Agent for Inflammatory Bowel Disease
Region	:	Japan
Application No.	:	2023-114129
Registration No.	:	To be determined
Applicant	:	StemRIM Inc., Osaka University

This patent secures the potential for developing Redasemtide (HMGB1 peptide), the "Regeneration-Inducing Medicine™", as a treatment for inflammatory bowel diseases (ulcerative colitis and Crohn's disease) in Japan.

Ulcerative colitis is a type of autoimmune disease where chronic inflammation in the inner lining of the colon leads to ulcer formation. It typically begins in the rectum and may spread throughout the colon, with symptoms ranging from mild to severe and varying significantly from person to person. Crohn's disease is a chronic inflammatory bowel disease that can cause inflammation in any part of the digestive tract, though it most commonly affects the small intestine and colon. Like ulcerative colitis, Crohn's disease is thought to involve an autoimmune response. The cause remains unclear, but it is believed to result from a combination of genetic, immune, and environmental factors. Both diseases tend to affect younger individuals, and the number of patients in Japan has been increasing annually.

In this patent, Redasemtide has demonstrated effectiveness in animal models of inflammatory bowel disease, showing the ability to suppress weight loss, reduce inflammation, and mitigate shortening of the large intestine and mucosal damage. Similar effects are expected to contribute to the treatment of inflammatory bowel diseases in humans.

The impact on the financial performance for the fiscal year ending July 31, 2025, is insignificant. We will promptly disclose any additional information that needs to be disclosed.

About StemRIM Inc.

StemRIM Inc. is a biotech venture which began at Osaka University with the goal of realizing a new type of medicine called "Regeneration-Inducing Medicine™". The overall aim is to achieve regenerative therapy effects equivalent to those of regenerative medicine, solely through drug administration, without using living cells or tissues. Living organisms have

inherent self-organizing abilities to repair and regenerate tissues that have been damaged or lost due to injury or disease. This ability arises from the presence of stem cells in the body that exhibit pluripotency i.e., can differentiate into various types of tissues. When tissues are damaged, these cells, therefore, exhibit proliferative and differentiative capabilities, promoting functional tissue regeneration. “Regeneration-Inducing Medicine™” is aimed at maximizing the tissue repair and regeneration mechanisms already present in the body. With this aim, StemRIM is currently developing one of its most advanced regenerative medicine products. Specifically, this product is designed to release (mobilize) mesenchymal stem cells from the bone marrow into the peripheral circulation upon administration, thus increasing the number of stem cells circulating throughout the body and promoting their accumulation in damaged tissues. Here, these stem cells should accelerate tissue repair and regeneration. Certain disease areas expected to benefit from “Regeneration-Inducing Medicine™” include epidermolysis bullosa (EB), acute phase cerebral infarction, cardiomyopathy, osteoarthritis of the knees, chronic liver disease, myocardial infarction, pulmonary fibrosis, traumatic brain injury, spinal cord injury, atopic dermatitis, cerebrovascular disease, intractable skin ulcers, amyotrophic lateral sclerosis (ALS), ulcerative colitis, non-alcoholic steatohepatitis (NASH), systemic sclerosis, and any other areas where treatment with extrapulmonary mesenchymal stem cells is promising.

Inquiries:

StemRIM Inc.
Management & Administrator Dept.
E-Mail: stemrim-ir@stemrim.com
Twitter: @StemRIM_Inc

For more information, please visit the StemRIM website (https://stemrim.com/english/)